HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Recurrent urinary infections in women: clinical trial of cephradine as a prophylactic agent.

Abstract
Cephradine 250 mg at night for 12 months was given as a prophylactic measure to 33 female patients of mean age 41.6 years, who had a history in the preceding 12 months of between three and 24 (median = 7) episodes of frequency and/or dysuria. When on such treatment the mean period between symptomatic attacks was 300 days, while before treatment attacks occurred at a mean frequency of 60.3 days. Thus, prophylactic cephradine increased the interval between attacks five-fold. In a total of 9002 patient-days of treatment, only five bacteriuric breakthrough infections occurred. 27% of the patients reported adverse effects "probably" or "possibly" related to treatment. Hence, cephradine appears to be as effective and better tolerated than macrocrystalline nitrofurantoin, presently the drug of choice for the prophylaxis of recurrent urinary infections.
AuthorsW Brumfitt, J M Hamilton-Miller
JournalInfection (Infection) Vol. 15 Issue 5 Pg. 344-7 ( 1987) ISSN: 0300-8126 [Print] Germany
PMID3319912 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Cephalosporins
  • Cephradine
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Bacteriuria (prevention & control)
  • Cephalosporins (therapeutic use)
  • Cephradine (adverse effects, therapeutic use)
  • Clinical Trials as Topic
  • Feces (microbiology)
  • Female
  • Humans
  • Middle Aged
  • Recurrence
  • Urinary Tract Infections (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: